

According to international oncologists, trabectedin is the therapeutic option of reference for the second line treatment of sarcoma

- **Trabectedin is a well-tolerated drug by patients for its low level of toxicity**
- **Oncologists from around the world met in Madrid to analyze the current therapeutic options to fight sarcoma**

Madrid, April 7th, 2017.- The importance of an early diagnosis, to encourage the presence of multidisciplinary teams, planification of the treatment based on the morphological diagnosis and the necessary availability of therapies for each different sarcoma subtype, were a few of the principles conclusions extracted from the second edition of the international congress, "Soft Tissue Sarcoma: Evidence & Experience", organized by PharmaMar.

With relation the two most common subtypes of soft tissue sarcoma, leiomyosarcoma and liposarcoma, oncologists from around Europe met to emphasize that trabectedin is the most adequate treatment option when the therapeutic objective is for a long-term stabilization of the tumor, guaranteeing a good quality of life for the patientⁱ. *"If we compare trabectedin with other drugs in the treatment of uterine leiomyosarcoma, for example, in the clinic we more frequently select trabectedin due to the long progression free survival (PFS) reported in phase II and phase III"*, explains **Dr Isabelle Ray-Coquard**, Medical Oncology Léon Bérard Center in Lyon, France.

With respect to liposarcomas, in a study carried out in patients with myxoid liposarcomas, trabectedin has shown an overall response rate of 51% and a median PFS of 14 monthsⁱⁱ. *"After 5 cycles of doxorubicin + ifosfamide, tumor progression occurred and treatment with trabectedin as 2nd line was maintained beyond 6 cycles achieving a long-lasting response and tumor controlⁱⁱⁱ"*, **Dr. Peter Reichardt**, Director, cancer center Berlin-Buch, Germany, stated.

The recommendations from the European Society of Medical Oncology (ESMO) published in its clinical guidelines on sarcoma, refer to the second-line administration of trabectedin for the treatment of all types of soft tissues sarcomas in an advanced state^{iv}. These guidelines also highlight that the efficacy of this compound in the treatment of leiomyosarcoma and liposarcoma has been demonstrated, as well as its clinical benefit in other histological subtypes^v.



Through real clinical cases, oncologists from the UK, France, Germany, Italy, Spain and Holland, have underlined, among other things, the importance of adapting the treatment to the characteristics and necessities of the patients. Quality of life is one of the most worrying aspects. In the case of trabectedin it is well tolerated by the patients for its low toxicity^{vi}.

About YONDELIS® (trabectedin)

YONDELIS® (trabectedin) is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, *Ecteinascidia turbinata*. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair. It is approved in close 80 countries in North America, Europe, South America and Asia for the treatment of advanced soft tissue sarcomas as a single-agent and for relapsed ovarian cancer in combination with DOXIL®/CAELYX® (doxorubicin HCl liposome injection) in the European Union. Under a licensing agreement with PharmaMar, Janssen Products, L.P. has the rights to develop and sell YONDELIS® globally except in Europe, where PharmaMar holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceuticals.

About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: + 34609493127
Paula Fernández – Media Relations Manager pfalarcon@pharmamar.com Mobile: +34 638796215
Phone: +34 918466000





Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

ⁱ Grignani G, et al. Future Oncol. 2015;11(11S):15-24

ⁱⁱ Grosso F, et al. The Lancet Oncol. 2007;8(7):595-602

ⁱⁱⁱ Martín-Broto J, et al. Future Oncol. 2017;13(1):23-31.

^{iv} The ESMO/European Sarcoma Network 2014; 25 (Suppl 3):iii102-iii112;

^v The ESMO/European Sarcoma Network 2014; 25 (Suppl 3):iii102-iii112;

^{vi} Demetri GD, et al. J Clin Oncol 34, 2016 (suppl; abstr 11061)